BIIB095 / Biogen - LARVOL DELTA

Pharmacodynamic Study of BIIB095 and BIIB074 in Healthy Participants and Participants With Painful Diabetic Polyneuropathy (clinicaltrials.gov) - P1b; N=0; Withdrawn; Sponsor: Biogen; N=175 ➔ 0; Not yet recruiting ➔ Withdrawn

Clinical • Enrollment change • Trial withdrawal • Diabetic Neuropathy • Pain

"$BIIB fresh new pipeline? New programs MS:BTK inh SMA: BIIB078/110/100 Pain: BIIB095 Ophtalmology: BIIB111/112 Neurocognitive disorders: BIIB104 Out MS: BIIB098 Ophthalmolog: BIIB087 Acute neurology: Natalizumab AD: Elembecestast Switch Parkinson to AD & Dementia: BIIB092 https://t.co/Vr96h9huu9" (@BursatilBiotech)

Alzheimer's Disease • CNS Disorders • Dementia • Gene Therapies • Genetic Disorders • Movement Disorders • Pain • Parkinson's Disease • Tauopathies And Synucleinopathies

Pharmacodynamic Study of BIIB095 and BIIB074 in Healthy Participants and Participants With Painful Diabetic Polyneuropathy (clinicaltrials.gov) - P1b; N=175; Not yet recruiting; Sponsor: Biogen; Trial completion date: Aug 2020 ➔ Jan 2022; Initiation date: Nov 2019 ➔ Jul 2020; Trial primary completion date: Aug 2020 ➔ Jan 2022

Clinical • Trial completion date • Trial initiation date • Trial primary completion date

Pharmacodynamic Study of BIIB095 and BIIB074 in Healthy Participants and Participants With Painful Diabetic Polyneuropathy (clinicaltrials.gov) - P1b; N=175; Not yet recruiting; Sponsor: Biogen

Clinical • New P1 trial

Evaluating the Safety, Tolerability, and Pharmacokinetics of BIIB095 in Healthy Participants (clinicaltrials.gov) - P1; N=80; Completed; Sponsor: Biogen; Recruiting ➔ Completed

Clinical • Trial completion